(r 2 >0.1) into single protein quantitative trait loci (pQTLs) and identified 539 pQTLs (284 unique proteins, 83 451 independent SNPs) with a conservative Bonferroni level of significance (p<8.72×10 -11 = 84 0.05/509,946/1124). For 21% of the assayed proteins we detected a cis-pQTL at a more liberal 85 significance cut-off of p<5x10 -8 . The full list is available as Supplemental Data 2. We then fine-mapped 86 our associations with variants imputed from the 1000-Genomes project database. Next, we attempted 87 replication of 462 associations that had a suitable genotyped tag SNPs (r 2 >0.8) in samples from 338 88 participants of the QMDiab study 12 . Of those, 234 associations were replicated at a Bonferroni level of 89 significance (p<1.08×10 -4 = 0.05/462), and an additional 150 showed nominal significance (p<0.05) in the 90 replication sample. We observed directional consistency between primary and replication sample for 91 215 of the 234 replicated SNPs. Discrepancy for the remaining 19 SNPs may be explained by changes in 92 major and minor allele coding between the two cohorts and ethnic differences. What is more, out of 208 93 associations that had 95% replication power (determined by sampling), 171 (82.2%) were replicated and 94 198 (95.2%) were nominally significant. Moreover, we replicated several associations previously 95 reported in aptamer-, immunoassay-, and mass-spectrometry-based studies, which demonstrated 96 concordance among these technologies ( Supplemental Table 1 Next, we identified and annotated putative causative and disease-relevant variants. We used the SNiPA 99 web-tool 13 to retrieve variant-specific annotations for all SNPs from the 1000-Genomes project in 100 linkage disequilibrium (LD) with an identified pQTL (LD r 2 >0.8). The annotations included primary effect 101 predictions, SNPs in experimentally identified regulatory elements (ENCODE), expression QTLs (eQTLs), 102 and disease associated variants. Of 384 annotated cis-pQTLs, 228 had a variant in the gene coding 103 region, whereof 74 were protein-changing. Eighty-eight had a variant in a regulatory element, and 179 104 had an eQTL that matched the associated protein. We complemented the pQTL annotation with 122 105 overlapping methylation QTLs (meQTLs) (Supplemental Data 2) and 14 overlapping metabolic QTLs 106 (mQTLs) ( Supplemental Table 6 ). With the GWAS catalogue as a reference, and by including publicly 107 available summary statistics data from 16 large disease GWAS consortia, we identified 83 GWAS 108 associations for 42 unique disease endpoints that overlapped with 57 pQTL loci ( Supplemental Table 7) . 109
With the Ingenuity Pathway Analysis database (IPA, Qiagen Inc.), we annotated 50 proteins as clinical or 110 pharmaceutical biomarkers ( Supplemental Table 8 ) and 43 as drug targets ( Supplemental Table 9 ), and 111 all of these had at least one replicated pQTL. 112
We used Gaussian graphical modelling (GGM) to connect 1092 proteins through 3943 Bonferroni-113 significant partial protein-protein correlation edges (Supplemental Data 3). Then, we added all 451 114 genetic pQTL variants as nodes, and connected them to the protein network through the 539 SNP-115 protein associations (Figure 1) . This network is freely available online, and it can be navigated via an 116 interactive web interface. Overall, we found that given our study power the blood plasma levels of over 117 20% of all assayed proteins were under substantial genetic control, and in some cases, this control 118 resulted in nearly total protein ablation (Figure 2) . Additionally, a wide-spread feature was the 119 convergence of multiple association signals to impact the levels of key proteins of biomedical and 120 pharmaceutical interest (Supplemental Figure 2) . 121
Trans-associations. Trans-associations are exceptionally valuable for identifying new pathways. These 122 associations establish causal links between proteins encoded at the GWAS loci and the blood levels of 123 one or several trans-encoded proteins. We identified 148 trans-pQTLs and replicated 55. Forty-nine 124 trans-pQTLs had 95% replication power, we replicated 38 of these. Six replicated trans-pQTLs had an 125 additional replicated cis-association, two had two replicated trans-associations and one had three 126 replicated trans-associations. Three independent SNPs at the haptoglobin (HP) locus had together four 127 pQTLs, and two proteins had replicated trans-associations at two distinct chromosome locations (Table  128 1). 129
In this study, the pleiotropic ABO blood group gene exhibited the most promiscuous protein association 130 signal. This locus displayed six independent genetic variants that were associated with 14 different 131 proteins through replicated trans-pQTLs; three of these associations had been published previously 132 (VWF, SELE, SELP, Supplemental Table 2 ). The other eleven associations were new, to our knowledge 133 (BCAM, CD200, CD209, CDH5, FLT4, INSR, KDR, MET, NOTCH1, TEK, TIE1). 134
Genetic variance in ABO has been associated with coronary artery disease and stroke 14 and diabetes 15 135 (Supplemental Figure 3) . The non-O blood group is one of the most important genetic risk factors for 136 venous thromboembolism 16 , pancreatic cancer 17 , and susceptibility to infectious diseases 18 . However, 137
we lack a full understanding of the proteins and pathways involved in the pathogenic effects of these 138 genetic variants. Based on the pQTLs reported here, we found support for the following new 139 hypotheses: (1) The association between ABO and the Insulin receptor (INSR) reflects the well-140 established associations between the ABO locus and diabetes and the insulin receptor and diabetes 15 . 141
The association between ABO and the Insulin receptor (INSR) suggest that INSR-mediated insulin 142 signaling may be involved in the ABO-diabetes association.
(2) rs651007 associated here with P-selectin 143 (SELP). SELP-positive platelets were previously reported to be associated with blood pressure 19 , and 144 rs651007 was associated in a GWAS with angiotensin converting enzyme (ACE) activity. This variant was 145 further identified as an mQTL for a number of dipeptides in blood 20 , which may be produced by the 146 dipeptidase ACE 21 . These observations suggest a potential role for the SELP pQTL in the GWAS 147 association between ABO and cardiovascular disease. (3) Several of the 14 proteins associated here with 148 ABO have been shown to interact or form complexes in relation with angiogenesis and vascular 149 maturation processes: Angiopoietin-1 receptor, soluble (TEK) plays a role in embryonic vascular 150 development and phosphorylates Tyrosine kinase with immunoglobulin-like and EGF-like domains 1 151 (TIE1). TIE1 overexpression in endothelial cells upregulates selectin E (SELE) 22 . Strain induced 152 angiogenesis is mediated in part through a Notch-dependent, Ang1/Tie2 signalling pathway that 153 implicates NOTCH1 and TIE1 23 . Vascular endothelial (VE)-cadherin (CDH5) is required for normal 154 development of the vasculature in the embryo and for angiogenesis in the adult, and it is associated 155 with VE growth factor (VEGF) receptor-2 (KDR) on the exposure of endothelial cells to VEGF 24 . 156
Heterodimers of KDR and Vascular endothelial growth factor receptor 3 (FLT4) positively regulate 157 angiogenic sprouting 25 . VEGF directly and negatively regulates tumor cell invasion through enhanced 158 recruitment of the Protein tyrosine phosphatase 1B (PTP1B) to a hepatocyte growth factor receptor 159 (MET) -KDR hetero-complex 26 . VEGF also synergistically increased tumor necrosis factor-alpha-induced 160 E-selectin mRNA and shedding of soluble E-selectin. Synergistic upregulation of E-selectin expression by 161 VEGF is mediated via KDR and calcineurin signaling 27 . These observations suggest that genetic variance 162 in ABO has major effects on a network comprising a number of proteins involved in cell adhesion, 163 angiogenesis and neo-vascularization processes. Consequently, the here reported trans-pQTLs indicate 164 novel pathways that may be involved in ABO-mediated cancer susceptibility in addition to regulating 165 vascular metabolism 28 . 166
Post-translational modifications. To follow up on the many hypotheses generated by the pQTLs 167 reported here, expert knowledge and experimentation will be required. Given the fact that several of 168 the proteins identified in our pQTLs were glycoproteins, we performed plasma protein glycoprofiling 169 (see Online Methods) to investigate whether our pQTLs were involved in post-translational protein 170
modifications. 171
For instance, SNP rs3760775, located near the FUT3 gene, was associated with plasma levels of the 172 corresponding galactoside3(4)-L-fucosyltransferase protein. We found that this same variant was 173 strongly associated with the N-glycan GP33 (p=1.4×10 -15 ) (see Figure 3A for GP33 structure). In a 174 previous GWAS, SNP rs3760775 was reported to be associated with the glycan antigen, CA19-9 29 , a 175 widely used cancer biomarker, which is present on multiple proteins 30 . Nearly 20 years ago, studies 176 demonstrated a similar association between CA19-9 and the FUT3 gene dosage 31,32 . This previously 177 reported association between variance in the FUT3 locus and the expression of cancer antigen, CA19-9, 178 and our observation of a similar association with GP33, suggest that both glycans may be involved in a 179 same pathway. 180
Another glycoprofile investigation began with the strong, genotype-dependent correlation between 181 complement factor C4 (C4) and the N-glycan, GP19 (p=2.0×10 -27 ) ( Figure 3D ). We also found that SNP 182 rs8283 was associated with both C4 and GP19. GP19 is composed of 9 mannose moieties (M9 glycan 183 structure), and it was previously reported to be attached to C4 33 . Moreover, M9 glycans are the 184 principal target ligand for mannose binding protein (MBL), which binds to C4 34 , and subsequently, 185 activates the complement system through the lectin pathway. MBL has been implicated in the pathology 186 of rheumatoid arthritis (RA) in many studies, including a recent meta-analysis, which confirmed the 187 association between functional MBL variants and RA risk 35 . The rs8283 variant was also associated with 188 RA (p=3.8×10 -51 ) 36 , but is not in linkage disequilibrium with the top reported RA-risk variants in the HLA 189 region. Hence, SNP rs8283 appears to be an independent signal, possibly mediated through MBL binding 190 to C4 glycans. 191 Biomedical relevance. A major challenge in conducting a disease GWAS is the difficulty in identifying 192 causative variants in the pathophysiological pathways that lead to the observed clinical manifestations. 193
Generally, hypotheses about the identity of the disease-causing genes are based on biological 194 arguments, such as the presence of SNPs in the regulatory or coding regions of functionally plausible 195 genes, which may be supported by co-associated eQTLs. However, a much stronger argument is 196 provided by the co-association with a pQTL, which constitutes firm experimental evidence that the 197 blood levels of disease-associated proteins vary in response to changes in the genome. Moreover, 198 partial correlations to functionally related proteins, as reported here, may further substantiate 199 hypotheses generated from pQTLs (see example in Figure 1C ). In the following sections, we show how 200 pQTLs identified in this study reveal new insights into multiple disease-associated pathways identified in 201 previous GWAS. 202
Auto-immune disorders. Ankylosing spondylitis (AS) is a common cause of inflammatory arthritis, and it 203 affects one in 200 Europeans. Evans et al. 37 identified two AS-risk variants in the endoplasmic reticulum 204 aminopeptidase 1 (ERAP1) gene; they reported that the major allele of rs30187 and the minor allele of 205 rs10050860 were protective. ERAP1 is involved in trimming peptides prior to HLA class I presentation; it 206 has recently attracted attention as a drug target for auto-immune disorders 38 . Several studies showed 207 that ERAP1 was present in blood; it was localized to exosome-like vesicles and present in the 208 extracellular space 39 . Here, we found that the two identified AS-risk variants were associated, in an 209 additive manner, with increasing levels of circulating ERAP1 protein (Figure 4A) . Similarly, mRNA 210 sequences isolated from lymphoblastoid cells showed that ERAP1 mRNA expression also increased with 211 increasing numbers of AS-risk alleles (Figure 4B) . Previous work concluded that the association between 212 ERAP1 and AS was mainly driven by genetic differences in how ERAP1 enzymatic activity shaped the 213 HLA-B27 peptidome 40,41 . Our findings suggest that the auto-immunogenic effects of different ERAP1 214 protein variants may be modulated by genotype-dependent regulation of protein expression. This 215 observation may have broader implications for treatment approaches to autoimmune disorders that 216 depend on ERAP1 antigen processing. 217
Complement system and haem clearance. We identified two independent variants (rs10494745 and 218 rs10801582), located in the complement factor H-related 2/4 (CFHR2/CFHR4) gene locus. These variants 219 were associated in trans with haemopexin (HPX) protein levels (Figure 2A) . Lower CFHR4 expression 220 levels were associated with lower HPX protein levels. HPX binds haem with high affinity and transports it 221 from the plasma to the liver, which prevents the accumulation of oxidative species. The rs10494745 222 variant is a GE amino acid substitution in CFHR4. It is an eQTL for CFHR4 expression in liver, as it tags 223 the GTEx rs4915318 variant (GTEx, p=1.6×10 -7 ). Imputed data revealed a third, strong, and independent 224 signal on SNP rs61818956 (p=1.13×10 -74 ), which is located in an intron in the CFHR2/CFHR4 locus. 225
Conditional analysis showed that all three variants were statistically independent, and together, they 226 explained a surprising 61% of the observed variance in a key protein responsible for oxidative stress 227 reduction. Previous studies reported that CFHR4 interacts with complement component 3 (C3) 42 , and in 228 turn, C3 interacts with haem 43 . Those findings suggest a plausible trans-acting pathway that links CFHR4 229 and HPX. That observation may have important consequences on our understanding of the pathologies 230 involved with the classical and alternative complement activation pathways. 231
Alzheimer's disease (AD) and mRNA splicing. Our findings on the major AD-risk variant, rs4420638, may 232 generate particular medical interest. This variant displayed a cis-association with increased levels of 233 apolipoprotein E (isoform E2) (APOE) and a concordant trans-association with decreased levels of small 234 nuclear ribonucleoprotein F (SNRPF). This dual association was further supported by the finding that the 235 ratio between APOE and SNRPF strengthened the association with rs4420638 by 16 orders of magnitude 236 (p-gain statistic 44 ). Although this association lacked sufficient replication power, both APOE and SNRPF 237 associations remained nominally significant in the QMDiab (p<0.012), with corresponding trends. SNRPF 238 is a core component of U1, U2, U4, and U5 small nuclear ribonucleoproteins (snRNPs), which are the 239 building blocks of the spliceosome. Recently, a knock-down of U1-70K or inhibition of U1 snRNP 240 components was shown to increase the levels of amyloid precursor protein 45 . An association between 241 this major AD-risk variant and a protein of the spliceosomal machinery has not been reported 242 previously. Taken together, these observations support the implication that protein splicing may be an 243 important factor in AD. Furthermore, the trans-association between SNP rs4420638 and SNRPF had 244 opposite directionality compared to that with APOE levels. These observations suggest that a regulatory 245 mediator is most likely involved. Theoretically, pharmacological targeting of this mediator could cause 246 an increase in SNRPF, which would increase splicing, and potentially decrease amyloid precursor protein 247 levels. 248
Pharmacogenetics.
A pQTL that harbours a drug target may affect patient response to treatment. For 249 example, we observed a strong, replicated cis-association between rs489286 and reduced blood levels 250 of the signalling lymphocytic activation molecule-F7 (SLAMF7) in carriers of the minor allele. This was 251 further confirmed with a SLAMF7-eQTL that showed identical directionality in mRNA sequencing data 252 from lymphoblastoid cell lines (Supplemental Figure 4) . Furthermore, imputed data identified a strong 253 association between SLAMF7 protein levels and a SNP in the SLAMF7 intron, rs11581248; heterozygous 254 alleles caused severely reduced SLAMF7 levels, and the homozygous minor allele nearly ablated the 255 SLAMF7 protein (Figure 2) . SLAMF7 is targeted by the recently FDA-approved cancer drug, Elotuzumab, 256 a humanized monoclonal antibody prescribed for relapsed or refractory multiple myeloma. Previously, a 257 small study on Japanese women indicated an association between rs17313034 (r 2 =0.82 with rs489286) 258 and cervical cancer 46 ; it showed that the minor allele had a protective effect. Taken together, these data 259 suggest the possibility that the response to Elotuzumab treatment may depend on the patient's 260 rs489286 genotype, and that rs11581248 homozygotes (1.5% of the population) may not respond to 261
Elotuzumab. We cannot exclude the possibility that rs17313034 might affect the SLAMF7 epitope, which 262 could potentially alter SLAMF7-aptamer binding. However, such an alteration might then also affect 263 Elotuzumab binding. This hypothesis can be tested retrospectively in the phase-3 clinical trial cohort 47 . 264
Drug target validation. Plenge et al. 48 suggested that naturally occurring genetic variance could be used 265 to validate drug targets, based on genotype-phenotype dose-response curves. For example, IL6R was 266 previously proposed as a target for preventing coronary heart disease. Recently, tocilizumab, a 267 humanized antibody that targets IL6R, was developed and is currently approved for treating rheumatoid 268 arthritis. Plenge et al. 48 required that, for validating drug targets, the gene must include multiple 269 causative variants of known biological function. A large, IL6R Mendelian randomization analysis 49 found 270 that SNP rs7529229 was associated with increased IL6R, reduced CRP, reduced fibrinogen, and reduced 271 odds of coronary heart disease (p=1.53×10 -5 ). The CardiogramPlus consortium GWAS data confirmed 272 that association (p=1.66×10 -8 ). In the present study, we replicated the IL6R-pQTL (rs4129267, r 2 =0.94 273 with rs7529229). Furthermore, we identified a second SNP in IL6R, rs11804305, which tags an 274 independent and causative variant, since rs4129267 was already established as functional. Therefore, 275 these two SNPs could be used to investigate dose-response curves in the huge dataset available from 276 the IL6R-Mendelian randomization consortium 49 . A similar approach is now feasible for all other protein 277 drug targets that were associated here with multiple pQTLs (for examples see Supplemental Figure 2 ). 278
What is more, the aptamers that were used in this study to target these proteins can readily be used as 279
intermediate readouts in assessing drug responses and in optimizing the efficacy of lead components. 280
Application to disease GWAS. Genetic associations with intermediate traits are generally much stronger 281 than associations with disease endpoints, due to their proximity to the causative variant, as shown in 282 our previous GWAS with metabolic traits 50 . Therefore, pQTLs can serve as proxies to fine-map genetic 283 disease associations. This approach can be used to identify potentially causative genes and additional 284 independent genetic signals at a locus identified in a disease-GWAS. In particular, pQTLs can be used to 285 identify true positive associations among associations that do not reach genome-wide significance. For 286 instance, rs12146727 was associated with cardiovascular disease (CVD; p=6.18×10 -5 ) in CardiogramPlus 287 and with AD (p=3.10×10 -5 in the discovery cohort (st1), and p=8.27×10 -6 in a combined analysis of a 288 larger cohort (st12comb)) in the International Genomics of Alzheimer's Project. A true positive 289 association requires that the association signal must be strengthened with increasing sample numbers, 290 which was the case for the st1 and st12comb cohorts. In the present study, rs12146727 was replicated 291 as a cis-pQTL for complement C1r subcomponent (C1R), and it was replicated as a trans-pQTL for 292 complement C1q subcomponent (C1QA/C1QB/C1QC). These associations support growing evidence that 293 suggests that the complement system plays a role in both AD and CVD 51 . This example also shows how 294 variants that associate with a disease endpoint could generate new hypotheses about the role of the co-295 associated protein(s) in the disease aetiology. Note that even when these variants have small effect sizes 296 or odds ratios, the related pathways may show large responses to pharmaceutical alteration of these 297 proteins. Hypotheses generated with this approach can be directly tested in animal models, and the 298 existing aptamers can be potentially used as intermediate functional readouts in the drug development 299 process. 300
DISCUSSION 301
Genetic studies with yeast 52 and lymphoblastoid cell lines 53-55 have indicated that cellular protein levels 302 are under strong genetic control. This control was confirmed by the discovery of many cis-acting genetic 303 variants in the human blood proteome 4-9 . Here, we described the first large-scale proteomics GWAS on 304 blood plasma proteins derived from a human population. This GWAS represented over 1.1 million 305 individual aptamer binding experiments. By design, our panel of more than 1100 aptamer targets was 306 highly enriched in biomedically-relevant blood circulating proteins, which was reflected in the large 307 overlap of pQTLs with risk loci identified in disease-GWAS. The data generated from this study can be 308 used in future investigations to identify and validate causative variants identified in disease GWAS. For 309 instance, aptamer-based read-outs can be used as intermediate traits in CrispR-based experiments, as 310 exemplified with the FTO-obesity association described by Claussnitzer et al. 56, 57 . 311 Surprisingly, we found that up to 60% of the naturally occurring variance in in the blood plasma levels of 312 essential proteins could be explained by two or more independent variants of a single gene located on 313 another chromosome. We identified strong genetic associations with intermediate, and most likely 314 functional, traits related to proteins involved in pathways to complex disorders. While many of our 315 associations connect these proteins to disease pathway through shared association, it should be borne 316 in mind that confounding is always a possibility that needs to be ruled out by further experimentation. 317
These findings can be used in future studies to establish dose-response curves for drug-target 318 validation 48 . A greater understanding of the genetic control of circulating levels of protein drug targets 319 and biomarkers may improve pharmaceutical interventions and clinical trials. Because all the aptamers 320 used in this study were synthetically generated and well defined, they can be readily developed into 321 specific assays for precise clinical applications. For instance, the SLAMF7-binding aptamer identified 322 here, which revealed a potential genetic effect on Elotuzumab, may be developed directly into a clinical 323 assay for identifying differential responders to immunotherapy. Moreover, this concept can be 324 generalized to other drug targets and biomarkers. 325
Despite the variable baseline conditions among the participants of the replication cohort (not fasting, 326 high prevalence of diabetes, and multiple ethnic backgrounds), we replicated 82% of all sufficiently 327 powered associations. This result emphasized the robustness of the replicated associations. It also 328 suggests that many of the Bonferroni-significant associations that could not be replicated in our QMDiab 329 cohort may be replicated in future studies. In this study, about 20% of all assayed proteins had a 330 significant pQTL association. This number is expected to increase in future more highly powered studies. 331
Genetic variance in a protein sequence may affect its higher order structure, and thus, its aptamer-332 binding affinity. Similarly, alterations in protein structure may affect binding and specificity in 333 immunoassay-based methods and protein mass in targeted MS-based methods. These issues remain to 334 be addressed. In this study, we showed that structural-based epitope effects on a particular pQTL may 335 be identified or ruled out in several ways, including: allele-specific transcription analysis (e.g., CPNE1, 336 Supplemental Figure 5 ); co-associated eQTLs, particularly when they include multiple genetic variants 337 (e.g., ERAP1, Figure 4) ; the absence of correlated SNPs that alter the protein structure (e.g., based on 338
SNiPA-annotated 1000 Genomes data), or replication on different platforms (Supplemental Table 2 
-5). 339
We did not directly follow up on our results using mass spectroscopy. However, Ngo et al. 58 recently 340 showed that response curves for selected aptamer-enriched proteins were linear over a wide dynamic 341 range of spiked protein concentrations. Most importantly, trans-associations, which were a central focus 342 of this study, are not affected by this type of potential artefact. 343
In summary, our GWAS demonstrated the power of linking the genome to disease endpoints via the 344 blood proteome. As we have shown at the examples, mining of our data can reveal a plethora of new 345 insights into biological processes and provide a wealth of functional information that is beyond the focus 346 of a single publication. Therefore, we have provided additional interpretations of selected loci in 347 drawn in the morning between 08:00 and 10:30 after a period of at least 10 h overnight fasting. Blood 370 was collected without stasis and was kept at 4 °C until centrifugation. The material was then centrifuged 371 for 10 min (2,750g at 15 °C). Plasma samples were aliquoted and stored at −80 °C until assayed on the 372 SOMAscan platform. QMDiab: Non-fasting plasma specimens were collected in the afternoon, after the 373 general operating hours of the morning clinic, and processed using standardized protocols. Cases and 374 controls were collected as they became available, in a random pattern and at the same location using 375 identical protocols, instruments and study personnel. Samples from cases and controls were processed 376 in the lab blinded to their identity. After collection the samples were stored on ice for transportation to 377 WCM-Q. Within six hours after sample collection all samples were centrifuged at 2,500g for 10 minutes, 378 aliquoted, and stored at -80°C until analysis. 379 380 Genotyping. KORA: The Affymetrix Axiom Array was used to genotype 3,788 participants of the KORA S4 381 study. After thorough quality control (total genotyping rate in the remaining SNPs was 99.8%) and 382 filtering for minor allele frequency >1%, a total of 509,946 autosomal SNPs was kept for the GWAS 383 analysis. 1000 Genomes Project-imputed genotypes were used for fine mapping and generation of 384 regional association plots (Supplemental Figure 6) . KORA genotype data has been reported previously 385 with many GWAS studies and was used here as-provided by the consortium. We therefore do not repeat 386 details here 11 . QMDiab: DNA was extracted from 359 samples from QMDiab and genotyped by the 387 WCM-Q genomics core facility using the Illumina Omni 2.5 array (version 8). High quality genotype data 388 of 2,338,671 variants was obtained for 353 samples; data for 6 samples was excluded due to a low 389 overall call rate (<90%). Removal of duplicate variants left 2,327,362 variants. 134,830 variants were 390 removed due to missing genotype data (PLINK option --geno 0.02), leaving 2,192,532 variants. 941,058 391 variants were removed due to minor allele threshold (PLINK option --maf 0.05), leaving 1,251,474 392 variants. 28,175 variants were removed due to violation of Hardy-Weinberg equilibrium (PLINK option --393 hwe 1E-6), leaving 1,223,299 variants. Of these variants, 1,221,345 were autosomal variants. The total 394 genotyping rate of these remaining variants was 99.7%. 395
396
Proteomics measurements. KORA: The SOMAscan platform was used to quantify protein levels. It has 397 been described in detail before 5,10,61-65 . Briefly, undepleted EDTA-plasma is diluted into three dilution 398 bins (0.05%, 1%, 40%) and incubated with bin-specific collections of bead-coupled SOMAmers in a 96-399 well plate format. Subsequent to washing steps, bead-bound proteins are biotinylated and complexes 400 comprising biotinylated target proteins and fluorescence-labeled SOMAmers are photocleaved off the 401 bead support and pooled. Following recapture on streptavidin beads and further washing steps, 402
SOMAmers are eluted and quantified as a proxy to protein concentration by hybridization to custom 403 arrays of SOMAmer-complementary oligonucleotides. Based on standard samples included on each 404 plate, the resulting raw intensities are processed using a data analysis work flow including hybridization 405 normalization, median signal normalization and signal calibration to control for inter-plate differences. 406 1,000 blood samples from the KORA F4 study were sent to SomaLogic Inc. (Boulder Colorado, USA) for 407 analysis. Two of the shipped samples were incorrectly pulled from the bio-bank and had no 408 corresponding genotype data, one sample failed SOMAscan QC, leaving a total of 997 samples from 483 409 males and 514 females for analysis. Data for 1,129 SOMAmer probes (SOMAscan assay V3.2) was 410 obtained for these samples. Five of the probes failed SOMAscan QC, leaving a total of 1,124 probes for 411 analysis ( Supplemental Table 1 all associations). Genomic inflation was low (mean=1.0035, max=1.0251). Therefore no correction for 426 genomic control was applied. To define genetically independent association loci, we lumped in a first 427 step for every given probe all associations with correlated SNPs (LD r 2 >0.1, window size 10Mb) and 428 retrieved the SNP that had the strongest association at the sentinel for this probe association. We then 429 grouped all highly correlated sentinel SNPs (LD r 2 >0.9, window size 10Mb) into single loci. We report 430 uncorrected association p-values throughout this paper. In all statistical analyses we require a nominal 431 significance level of 0.05 (alpha error 5%). Multiple hypotheses testing is accounted for by using 432 conservative Bonferroni correction of the significance level, based on the number of tested SNPs 433 (509,946) and probes (1,124), resulting in a genome-and proteome-wide significance level of 434 p<8.72×10 -11 (0.05/509,946/1,124). 451 loci had at least one Bonferroni significant sentinel association. 435
For each of these 451 loci, we also considered all probe associations with that same SNP at a significance 436 level of p<9.86×10 -8 (0.05/451/1,124) as Bonferroni significant. This resulted in a total of 539 genetic 437 association signals (284 unique probes), each represented by a sentinel SNP and one or more sentinel 438 probes, including 391 cis-associations (defined by a SNP closer than 10Mb from the gene boundaries, Replication. Using the QMDiab proteomics data as dependent variables, linear regression models were 446 fitted with PLINK (version 1.90, version b3w), using age, sex, BMI, diabetes state, the first three principal 447 components (PCs) of the genotype data and the first three PCs of the proteomics data as covariates. The 448 first three genetic PCs separate the three major ethnicities and the three proteomics PCs account for 449 variability introduced by a low degree of cell haemolysis. Genomic inflation was low (mean=1.020, 450 max=1.116). Therefore no correction for genomic inflation was applied. A tag SNP for replication of each 451 of the 451 Bonferroni significant loci was selected by using the strongest association among all imputed 452 SNPs in the discovery study which had a correlation of r 2 >0.8 with the sentinel SNP. 387 tag SNPs for the 453 451 originally identified SNPs could be identified for replication, covering 462 SNP-probe pairs out of the 454 originally identified 539 SNP-probe pairs. To consider an association as replicated, we therefore required 455 p<1.08×10 -4 (0.05/462). 234 (50.6%) of the 462 attempted replications fully replicated at a Bonferroni 456 level of significance (p<0.05/462), 384 (83.1%) displayed nominal significance (p<0.05). Out of 84 non-457 replicated associations that were nominally significant and that had a MAF<30% in both cohorts, only 458 one association displayed a discordant trend. We estimated the statistical power for the replication by 459 sampling: For each association we randomly selected without replacement 338 individuals from the 460 KORA cohort and computed the p-value of association on that subset. We repeated this 100 times and 461 report the 5 th largest p-value from this empirical distribution as the p-value that can be expected to be 462 obtained with 95% power (p95). Based on this analysis we found that 208 SNP-probe pairs with a 463 suitable tag SNP in QMDiab had 95% replication power (p95<1.08×10 -4 ). 171 of these 208 (82. these associations had a suitable tag SNP in the genotyped KORA data set (r 2 >0.5) or association data on 469 an imputed SNP that allowed for replication. 34 of these SNPs were replicated (p<0.05/120, 470 conservatively accounting for replication attempts on tagged and imputed SNPs). The first non-471 replicated association had rank 21 ( Supplemental Table 3 ). Table 1 ). Some SOMAmer targets map to multiple Uniprot identifiers (N=41). They either 499 refer to protein complexes (N=32) that are encoded at multiple genome loci, or to different variants of a 500 same protein encoded at a single gene locus (N=9). 1,090 SOMAmer targets were encoded on 501 autosomal chromosomes, 30 targets were encoded on the X-chromosome, and four targeted viral 502 proteins. Genome positions for all SOMAmer targets were retrieved from Ensembl 503 (http://www.ensembl.org) using probe-specific Uniprot identifiers provided by SomaLogic. We used 504
Ingenuity Pathway Analysis (IPA) (http://www.ingenuity.com/products/ipa) to retrieve additional 505 information related to each probe. IPA provides a rich expert-curated knowledgebase of literature-506 based protein-related information and requires unique mapping to protein identifiers. Forty-one probes 507 were present that target proteins with multiple Uniprot IDs, and these were excluded from the IPA 508 analysis. A further 29 probes were excluded because multiple probes target a same protein. Eight 509 Uniprot IDs could not be mapped by IPA (LAG-1, LD78-beta, NKG2D, HSP 70, and four viral proteins). 510
Ultimately, 1,045 probes with unique Uniprot IDs remained for the IPA annotation. 511 512 Functional annotation of the associations. We used the SNiPA server (v3.1, http://snipa.org) to 513 annotate 435 out of our 451 lead SNPs (Supplemental Figure 9) . 16 SNPs were not available in the SNiPA 514 database. SNiPA provides annotations for all SNPs that are in linkage disequilibrium (R 2 >0.8) with and no 515 more than 500kb distant from a sentinel SNP using genome assembly data based on GRCh37.p13, 516
Ensembl version 82, 1000-Genomes (phase 3, version 5) data, and GTEx (release 4) eQTL associations for 517 13 tissues (see columns SNIPA_... in Supplemental Data 2). SNiPA also provides primary effect 518 predictions using the Ensembl VEP tool 67 and all GWAS association data from the GWAS catalog 68 gender + bmi (997 samples with data for 1,124 variables) we computed a GGM using the 570 ggm.estimate.pcor function from the R GeneNet package. The estimated optimal shrinkage intensity 571 lambda (correlation matrix) was 0.187. We obtained 3,943 GGM edges connecting 1,092 protein nodes 572 with Bonferroni significant partial correlation coefficients (p< 7.9×10 -8 = 0.05/(1,124*1,123/2)), provided 573 as Supplemental Data 3. We added SNP-probe association edges connecting 451 genetic loci to 539 574 proteins. We further added SNP-disease association edges using all associations reported in the GWAS 575 catalogue (identified using SNiPA at LD r 2 >0.8). We also added all SNP-disease associations from 84 576 clinically relevant traits of 14 large GWAS consortia that had a p-value P<10 -8 . These SNP-disease edges 577 were further manually curated to ascertain unique SNP-disease pairs. SNP association to disease-related 578 protein levels were excluded. 579
580
Data Availability. All summary statistics and association data are freely available, accessible online on an 581 integrated web-server at http://proteomics.gwas.eu. A fully functional version of the web-server can 582 also be freely downloaded from this link for local installation and network-free usage (HTML5-based, no 583 extra software is required). The informed consent given by the study participants does not cover posting 584 of participant level phenotype and genotype data in public databases. However, data are available upon 585 request from KORA-gen (http://epi.helmholtz-muenchen.de/kora-gen). Requests are submitted online 586 and are subject to approval by the KORA board. 587 Loci that comprise at least one replicated trans-association. Loci are referenced in this study by numbers ranging from 1 to 451 (strongest to 843 weakest) and sorted here by chromosome position. P-values are for the association with inverse-normal scaled protein levels; see Supplemental  844 Data 2 for full data of all 539 SNP-protein associations at 451 loci, including statistics for association with alternatively raw-and log-normal-845 scaled protein levels and estimated replication power. Candidate genes for the protein associations were annotated by considering the following 846 criteria: a variant in LD with the sentinel SNP (r2>0.8) is located in the gene transcript (a), a variant hits a regulatory element of that gene (b), a 847 variant is a cis-eQTL (c), a variant is a trans-eQTL (d), a variant is protein changing (e). The list of candidate genes in this table is limited to the five 848 most plausible candidate genes for each locus; the full list is available online and in Supplemental Data 2. Every trans-pQTL implies the existence 849 of a functional and causal link between a cis-encoded candidate gene and the target protein(s). 850
END NOTES 746

